Lipshultz SE, Orav EJ, Wilkinson JD, et al, for the Pediatric Cardiomyopathy Registry Study Group. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013 Dec 7. 382 (9908):1889-97. [QxMD MEDLINE Link].
El-Saiedi SA, Seliem ZS, Esmail RI. Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients. Cardiol Young. 2014 Aug. 24 (4):702-8. [QxMD MEDLINE Link].
Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002 Apr. 109 (8):1013-20. [QxMD MEDLINE Link]. [Full Text].
Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989 Nov 16. 321 (20):1372-8. [QxMD MEDLINE Link].
Sabater-Molina M, Perez-Sanchez I, Hernandez Del Rincon JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: a review of current state. Clin Genet. 2017 Apr 3. [QxMD MEDLINE Link].
Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012 Sep. 164 (3):442-8. [QxMD MEDLINE Link].
Hindieh W, Adler A, Weissler-Snir A, Fourey D, Harris S, Rakowski H. Exercise in patients with hypertrophic cardiomyopathy: A review of current evidence, national guideline recommendations and a proposal for a new direction to fitness. J Sci Med Sport. 2017 Apr. 20 (4):333-8. [QxMD MEDLINE Link].
Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007 Feb 13. 115 (6):773-81. [QxMD MEDLINE Link].
Ziolkowska L, Turska-Kmiec A, Petryka J, Kawalec W. Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatr Cardiol. 2016 Mar. 37 (3):448-58. [QxMD MEDLINE Link].
McCaffrey FM, Braden DS, Strong WB. Sudden cardiac death in young athletes. A review. Am J Dis Child. 1991 Feb. 145 (2):177-83. [QxMD MEDLINE Link].
Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996 Jul 17. 276 (3):199-204. [QxMD MEDLINE Link].
Rao PS. Prevention of sudden death in athletes. Pediat Therapeut. 2015 Aug 20. 5:e129. [Full Text].
Maron BJ, Spirito P, Ackerman MJ, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Apr 9. 61 (14):1527-35. [QxMD MEDLINE Link].
Bolin E, Lam W. A review of sensitivity, specificity, and likelihood ratios: evaluating the utility of the electrocardiogram as a screening tool in hypertrophic cardiomyopathy. Congenit Heart Dis. 2013 Sep-Oct. 8 (5):406-10. [QxMD MEDLINE Link].
[Guideline] Gersh BJ, Maron BJ, Bonow RO, et al, for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Tho... J Am Coll Cardiol. 2011 Dec 13. 58 (25):e212-60. [QxMD MEDLINE Link].
Jay A, Chikarmane R, Poulik J, Misra VK. Infantile hypertrophic cardiomyopathy associated with a novel MYL3 mutation. Cardiology. 2013. 124 (4):248-51. [QxMD MEDLINE Link].
Cortez D, Sharma N, Cavanaugh J, et al. The spatial QRS-T angle outperforms the Italian and Seattle ECG-based criteria for detection of hypertrophic cardiomyopathy in pediatric patients. J Electrocardiol. 2015 Sep-Oct. 48 (5):826-33. [QxMD MEDLINE Link].
Fulton N, Rajiah P. Utility of magnetic resonance imaging in the evaluation of left ventricular thickening. Insights Imaging. 2017 Apr. 8 (2):279-93. [QxMD MEDLINE Link].
Guerrero I, Dhoble A, Fasulo M, et al. Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2016 Nov 15. 88 (6):971-7. [QxMD MEDLINE Link].
[Guideline] Elliott PM, Anastasakis A, Borger MA, et al, for the authors/task force members. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14. 35 (39):2733-79. [QxMD MEDLINE Link].
Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm. 2005 Aug. 2 (8):814-9. [QxMD MEDLINE Link].
Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008 Apr 29. 51 (17):1685-91. [QxMD MEDLINE Link].
Kaski JP, Tome Esteban MT, Lowe M, Set al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart. 2007 Mar. 93 (3):372-4. [QxMD MEDLINE Link]. [Full Text].
Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007 Jul 25. 298 (4):405-12. [QxMD MEDLINE Link].
[Guideline] Epstein AE, DiMarco JP, Ellenbogen KA, et al, for the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices), AATS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 May 27. 51 (21):e1-62. [QxMD MEDLINE Link].
Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008 Jul 8. 118 (2):131-9. [QxMD MEDLINE Link].
Beadle R, Williams L. Device therapy in hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2010 Dec. 8 (12):1767-75. [QxMD MEDLINE Link].
Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J. 2010 Nov. 74 (11):2271-82. [QxMD MEDLINE Link].